This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Berthezène, F. Search for Related Content Social Bookmarking                         What's this?

Diabetic dyslipidaemia

Department of Endocrinology, Université Claude Bernard and Hospices Civils de Lyon, Lyon F-69394, France, francois.berthezene{at}chu-lyon.fr

Dyslipidaemia is likely to play a leading role in the cardiovascular risk associated with diabetes. Diabetic dyslipidaemia is characterised by hypertriglyceridaemia, a shift from large low-density lipoprotein (LDL) to smaller denser particles, and reduced high-density lipoprotein (HDL) cholesterol. Dyslipidaemia is closely associated with insulin resistance.

Patients with diabetic dyslipidaemia should receive lipid lowering therapy with statins or fibrates, as appropriate.

Due to the relationship between dyslipidaemia and insulin resistance, treatment of insulin resistance should be included in multifactorial risk factor modification. Thiazolidinediones such as pioglitazone may provide a useful treatment approach.

Key Words: diabetes • dyslipidaemia • fibrates • HDL • LDL • statins • triglycerides.

References

• Taskinen MR Strategies for the management of diabetic dyslipidaemia. Drugs 1999;58(suppl 1):47-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.[Abstract/Free Full Text]
• Sacks FM, Pfeffer MA, Moyé LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol And Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-9.[Abstract/Free Full Text]
• The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Shepherd J., Cobbe SM, Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-7.[Abstract/Free Full Text]
• Elkeles RS, Diamond JR, Poulter C. et al. Cardiovascular outcomes in Type
• diabetes. A double-blind placebo-controlled study of bezafibrate: the St Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998;21:641-8.[Abstract]
• Diabetes Atherosclerosis Intervention Study. Lancet 2001;357:905-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pyörälä K., Pedersen TR, Kjekshus J., Faergeman O., Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.[Abstract]
• Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation 1998;98:2513-9.[Abstract/Free Full Text]
• Turner RC, Millns H., Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-8.[Abstract/Free Full Text]
• Hanefeld M., Fischer S., Julius U. et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fontbonne A., Eschwege E., Cambien F. et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sowers JR, Lester MA Diabetes and cardiovascular disease. Diabetes Care 1999;22(suppl 3):C14-C20.[Web of Science][Medline] [Order article via Infotrieve]
• Elchebly M., Porokhov B., Pulcini T., Berthezène F., Ponsin G. Alterations in composition and concentration of lipoproteins and elevated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus (NIDDM). Atherosclerosis 1996;123:93-101.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Calvo C., Talussot C., Ponsin G., Berthezène F. Non-enzymatic glycation of apolipoprotein A-1. Effects on its self-association and lipid binding properties. Biochem Biophys Res Comm 1988;153:1060-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hedrick CC, Thorpe SR, FU M-X et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000;43:312-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Tilly-Kiesi M., Syvanne M., Kuusi T., Lahdenpera S., Taskinen MR Abnormalities of low density lipoproteins in normolipidaemic Type II diabetic and nondiabetic patients with coronary artery disease. J Lipid Res 1992;33:333-42.[Abstract]
• Calvo C., Luo B.-Y, Puygranier F., Ponsin G., Berthezène F. Characterization and metabolism of glycated high density lipoproteins in diabetic patients. Adv Exp Med Biol 1988;243:165-72.[Medline] [Order article via Infotrieve]
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gaudet D., Vohl MC, Perron P. et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 1998;97:871-7.[Abstract/Free Full Text]
• Garg A., Bonanome A., Grundy SM, Zhang ZJ, Unger RH Comparison of a high-carbohydrate diet with a high-monounsaturated-fat diet in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1988;319:829-34.[Abstract]
• Tikkanen MJ, Laakso M., Ilmonen M. et al. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care 1998;21:477-1.[Abstract]
• Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ 2001;323:359.[Free Full Text]
• Sacks FM, Tonkin AM, Shepherd J. et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900.[Abstract/Free Full Text]
• The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21-7.[Abstract/Free Full Text]
• Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low- levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.[Abstract/Free Full Text]
• Després J-P., Lamarche B., Mauriège P., Cantin B., Dagenais GR, Moorjani S., Lupien P.-J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 1 suppl, S12-S17 (2002)
DOI: 10.1177/14746514020020010401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Berthezène, F. Search for Related Content Social Bookmarking                         What's this?